United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, Bank of America Analyst Says

United Therapeutics (NASDAQ:UTHR) had its target price boosted by equities researchers at Bank of America from $569.00 to $626.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Bank of America‘s price target suggests a potential upside of 9.77% from the company’s current price.

Other analysts have also recently issued reports about the company. Wells Fargo & Company boosted their price objective on United Therapeutics from $466.00 to $486.00 and gave the stock an “equal weight” rating in a report on Monday, March 23rd. Oppenheimer lifted their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. HC Wainwright boosted their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Cantor Fitzgerald increased their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Royal Bank Of Canada raised their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $586.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $570.27 on Tuesday. The business’s fifty day moving average price is $502.93 and its two-hundred day moving average price is $476.94. The firm has a market capitalization of $24.99 billion, a price-to-earnings ratio of 20.44, a PEG ratio of 1.72 and a beta of 0.75. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $6.19 earnings per share. As a group, research analysts forecast that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.90, for a total value of $5,359,000.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,115,648.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $23,938,901.40. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 333,820 shares of company stock valued at $165,495,478 in the last ninety days. 10.30% of the stock is owned by insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC bought a new stake in shares of United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC grew its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1 results: Tyvaso met the trial’s key endpoint in idiopathic pulmonary fibrosis (IPF), driving a sharp runup in the stock because success expands Tyvaso’s addressable market beyond pulmonary arterial hypertension. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Company press release and institutional coverage reinforced the data readout, giving investors more confidence in a potential FDA filing and commercial upside for Tyvaso in IPF. United Therapeutics reports positive results for lung drug
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (Bank of America, Wells Fargo, HC Wainwright, others) followed the TETON‑1 readout, amplifying buying pressure and pre‑market gaps. Higher targets highlight expected revenue expansion if IPF approval/commercialization succeeds. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Positive Sentiment: Sell‑side momentum: some firms (e.g., HC Wainwright) moved to Buy and raised targets materially, which supports further upside if clinical and regulatory paths stay on track. HC Wainwright raises UTHR price target to $660
• Neutral Sentiment: Valuation check: analysts and market write‑ups are reassessing UTHR’s valuation after the IPF data — positive clinical news boosts forward revenue expectations but raises near‑term valuation scrutiny. Investors should weigh upside against higher multiples. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Neutral Sentiment: Options flow and momentum trading: unusually high options activity and gap‑up headlines indicate speculative positioning that can amplify moves and volatility around catalysts (e.g., filings, guidance). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Sell‑side balance: some firms raised targets but left neutral/equal‑weight ratings, reflecting disagreement on upside vs. execution risk; that keeps upside concentrated in execution and regulatory milestones. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Near‑term caution: some commentary flags valuation and execution risk plus mixed earnings‑estimate revision trends — these could limit further near‑term gains unless management provides clear regulatory/launch guidance. United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.